[ XXXX in acute and long-term therapy].

@entity1 @entity296 @entity712 @entity390 @entity882 @entity591 @entity11073 @entity951 @entity5052 @entity453
The purpose of this study was to evaluate acute and chronic therapeutic effects of the positive inotropic vasodilating agent @entity11073 . 50 @entity1 with @entity296 or @entity453 and @entity712 participated in the study. Swan-Ganz catheterisation was used in 15 @entity1 ; following injection of 1.5 mg/kg @entity11073 , the mean pulmonary pressure decreased by 26%, the wedge pressure by 27%. Cardiac index rose by 18% (p less than 0.01). 35 @entity1 were examined in the oral study, the avg. dose being 300 mg/day. After 2 and 12 weeks of therapy, exercise tolerance increased by 22% and 13% respectively (p less than 0.05). Cardiac output after maximal workload as determined by equilibrium radionuclide ventriculography increased by 27% and 30% respectively (p less than 0.05). 34 side effects occurred in 23 of 35 @entity1 : @entity390 , orthostasis, @entity951 , @entity591 , hepatotoxicity, @entity882 , @entity5052 and brown coloring of finger-nails. From the hemodynamic point of view @entity11073 is intravenously and orally effective. Careful selection of @entity1 and frequent examinations are however necessary.
